Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2021

View Archived Issues

Onconova opens enrollment in phase I study of ON-123300 in advanced cancer

Vertex to advance VX-548 into phase II development in acute pain

Pharmacological target for anorexia

Loss of cell polarity is lung cancer precursor

China's NMPA approves IND for IL-23p19-targeting antibody NBL-012

New kappa-opioid receptor agonists identified at Nippon Chemiphar

ViiV Healthcare presents new anti-HIV compounds

Domain Therapeutics discovers PTGER4 antagonists

New IRAK-4 inhibitors identified at Bayer

RP Scherer Technologies patents anti-CD25 antibody-maytansine conjugates

Roche initiates phase II study of RO-7121661 and RO-7247669 in ESCC

Phase II study finds evidence of improvement with SEP-363856 in psychosis in schizophrenia

KRAS G12C inhibitor BI-1823911 shows in vivo efficacy, to enter clinical study

Veyonda may prevent cytokine storm in moderately severe COVID-19

Brain iron accumulation is higher in patients with Parkinson's disease

Alkermes initiates global phase II trial of nemvaleukin alfa in melanoma

China NMPA clears initiation of global phase III study of cadonilimab in advanced cervical cancer

Phase III INVIGORATE trial of reproxalap in allergic conjunctivitis meets endpoints

New 2.5-year treatment data on vamorolone in Duchenne muscular dystrophy

Cell death finding may improve stroke management

Hillhurst cleared by FDA to begin phase I study of HBI-002 for sickle cell disease

Sorrento updates oncology pipeline progress

FDA issues complete response letter for pegunigalsidase alfa in Fabry disease

CLES in advanced Parkinson's disease: long-term effects

Hisamitsu reports phase III results with HP-5070 in primary palmar hyperhidrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...